Correction to: Adverse event management in the TOURMALINE-MM3 study of post-transplant ixazomib maintenance in multiple myeloma

Martin Kaiser^{1,2} · Meral Bektaş³ · Nina Gulbrandsen⁴ · Fredrik Schjesvold⁴ · Roman Hájek⁵ · Philippe Moreau⁶ · Felipe de Arriba de la Fuente⁷ · María-Victoria Mateos⁸ · Sharon West¹ · Andrew Spencer⁹ · S. Vincent Rajkumar¹⁰ · Kaveri Suryanarayan¹¹ · Michael Czorniak¹¹ · Cong Li¹¹ · Zhaoyang Teng¹¹ · Richard Labotka¹¹ · Meletios A. Dimopoulos¹²

Published online: 27 October 2020

© Springer-Verlag GmbH Germany, part of Springer Nature 2020

Correction to: Annals of Hematology

<https://doi.org/10.1007/s00277-020-04149-5>

Low-resolution figures were inadvertently created during production and published. These have been replaced with the high-resolution figures that were originally provided by the authors. No changes have been made to the data presented within the figures or to any other manuscript content.

Please see below for the high-resolution figures:

The online version of the original article can be found at <https://doi.org/10.1007/s00277-020-04149-5>

✉ Martin Kaiser
Martin.Kaiser@icr.ac.uk

¹ Department of Haematology, The Royal Marsden Hospital, London, UK

² Division of Molecular Pathology, The Institute of Cancer Research (ICR) and The Royal Marsden Hospital, 123 Old Brompton Road, London SW7 3RP, UK

³ Department of Hematology, Ankara University, Ankara, Turkey

⁴ Oslo Myeloma Center, Oslo University Hospital, and KG Jebsen Center for B Cell Malignancies, University of Oslo, Oslo, Norway

⁵ Department of Hematooncology, University Hospital Ostrava, Ostrava, Czech Republic

⁶ Department of Hematology, University Hospital Hôtel-Dieu, Nantes, France

⁷ Servicio de Hematología y Oncología Médica, Hospital Universitario Morales Meseguer y Centro Regional de Hemodonación, IMIB-Arrixaca, Universidad de Murcia, Murcia, Spain

⁸ Department of Hematology, University Hospital of Salamanca, CIC, IBM CC, Salamanca, Spain

⁹ Malignant Haematology and Stem Cell Transplantation Service, Alfred Health-Monash University, Melbourne, Australia

¹⁰ Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA

¹¹ Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USA

¹² Hematology and Medical Oncology, Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece

Fig. 1 CONSORT diagram.
Reproduced with permission
from Dimopoulos MA, Gay F,
Schjesvold F et al. Oral ixazomib
maintenance following
autologous stem cell
transplantation (TOURMALINE-
MM3): a double-blind,
randomised, placebo-controlled
phase 3 trial. *Lancet*
2019;393:253–264

Fig. 2 Cumulative incidence of new-onset thrombocytopenia (a) and median platelet counts (b) over time in the ixazomib and placebo groups, and actions taken for events of thrombocytopenia (c). Note: More than one action could be taken for a single event of thrombocytopenia

Fig. 3 Incidence rate by cycle (**a**) and cumulative incidence (**b**) of new-onset nausea. Only one patient in the ixazomib arm (< 1%) and no patients in the placebo arm had grade ≥ 3 nausea. Incidence rate is the

number of events in a cycle divided by the sum of patient cycles at risk in a cycle. A patient with an ongoing AE could not be at risk of getting the same AE until it was resolved

Fig. 4 Incidence rate by cycle (a) and cumulative incidence (b) of new-onset vomiting. No patients in the placebo arm had grade ≥ 3 vomiting. Incidence rate is the number of events in a cycle divided by the sum of patient cycles at risk in a cycle. A patient with an ongoing AE could not be at risk of getting the same AE until it was resolved

Fig. 5 Incidence rate by cycle (**a**) and cumulative incidence (**b**) of new-onset diarrhea. Incidence rate is the number of events in a cycle divided by the sum of patient cycles at risk in a cycle. A patient with an ongoing AE could not be at risk of getting the same AE until it was resolved

Fig. 6 Cumulative incidence of new-onset PN. Only one patient in the ixazomib arm had grade 3 PN (< 1%), and no patients in either arm had grade 4 PN

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.